Comparative Pharmacology
Head-to-head clinical analysis: PROSTAPHLIN versus UNASYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROSTAPHLIN versus UNASYN.
PROSTAPHLIN vs UNASYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prostaphlin (oxacillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP1 and PBP3, leading to inhibition of transpeptidation and cell lysis. It is resistant to staphylococcal beta-lactamases.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs); sulbactam is a beta-lactamase inhibitor that prevents degradation of ampicillin by beta-lactamases.
250-500 mg IM or IV every 4-6 hours for moderate to severe infections. For oral use: 250-500 mg every 6 hours on empty stomach.
3 g (ampicillin 2 g + sulbactam 1 g) IV every 6 hours; total daily dose of sulbactam not to exceed 4 g.
None Documented
None Documented
0.4-0.8 hours in adults with normal renal function; prolonged in renal impairment (up to 4-6 hours in anuria).
Ampicillin: ~1 hour (normal renal function); sulbactam: ~1-1.4 hours (normal renal function); prolonged in renal impairment (ampicillin up to 20 hours, sulbactam up to 10-15 hours in anuria).
Primarily renal (70-80% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Renal: ampicillin (~75-90% unchanged) and sulbactam (~75-85% unchanged); biliary/fecal: minimal (<5% for each component).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic